Provider: Sadif Analytics Prime
Swedish Orphan Biovitrum publ AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Swedish Orphan Biovitrum publ AB issues FY 2014 gross margin guidance and FY 2014 revenue guidance in line with analysts' estimates
Swedish Orphan Biovitrum publ AB:Says it expects total revenues for the full year 2014 to be in the range of between 2,300 mln Swedish crowns and 2,500 mln Swedish crowns and the gross margin to be in the range of between 58 pct and 60 pct.FY 2014 revenues 2,353.59 mln Swedish crowns - Thomson Reuters I/B/E/S.
Latest Developments for Swedish Orphan Biovitrum publ AB
- Biogen Idec and Swedish Orphan Biovitrum AB announce positive top-line results of Kids B-LONG Phase 3 clinical study
- Swedish Orphan Biovitrum issues FY 2015 guidance with revenue outlook in line with analysts estimates
- Swedish Orphan Biovitrum says EU approves Xiapex
- Swedish Orphan Biovitrum publ AB confirms FY 2014 guidance
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this